|
Name |
Maesopsin
|
| Molecular Formula | C15H12O6 | |
| IUPAC Name* |
2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one
|
|
| SMILES |
C1=CC(=CC=C1CC2(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
|
| InChI |
InChI=1S/C15H12O6/c16-9-3-1-8(2-4-9)7-15(20)14(19)13-11(18)5-10(17)6-12(13)21-15/h1-6,16-18,20H,7H2
|
|
| InChIKey |
LOFYFDPXORJJEE-UHFFFAOYSA-N
|
|
| Synonyms |
Maesopsin; 5989-16-2; Mesopsin; 3(2H)-Benzofuranone, 2,4,6-trihydroxy-2-((4-hydroxyphenyl)methyl)-; CHEMBL462109; SCHEMBL9957960; DTXSID90975298; CHEBI:181507; 2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one; LMPK12130072; Maesopsin, >=90% (LC/MS-ELSD); 2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzouran-3-one; 2,4,6-Trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3(2H)-one; NCGC00385382-01!2,4,6-trihydroxy-2-[(4-hydroxyphenyl)methyl]-1-benzofuran-3-one
|
|
| CAS | 5989-16-2 | |
| PubChem CID | 160803 | |
| ChEMBL ID | CHEMBL462109 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 288.25 | ALogp: | 2.2 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 107.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 21 | QED Weighted: | 0.671 |
| Caco-2 Permeability: | -5.127 | MDCK Permeability: | 0.00000974 |
| Pgp-inhibitor: | 0.012 | Pgp-substrate: | 0.02 |
| Human Intestinal Absorption (HIA): | 0.031 | 20% Bioavailability (F20%): | 0.95 |
| 30% Bioavailability (F30%): | 0.97 |
| Blood-Brain-Barrier Penetration (BBB): | 0.039 | Plasma Protein Binding (PPB): | 93.40% |
| Volume Distribution (VD): | 0.641 | Fu: | 4.81% |
| CYP1A2-inhibitor: | 0.82 | CYP1A2-substrate: | 0.44 |
| CYP2C19-inhibitor: | 0.179 | CYP2C19-substrate: | 0.061 |
| CYP2C9-inhibitor: | 0.477 | CYP2C9-substrate: | 0.902 |
| CYP2D6-inhibitor: | 0.584 | CYP2D6-substrate: | 0.67 |
| CYP3A4-inhibitor: | 0.877 | CYP3A4-substrate: | 0.214 |
| Clearance (CL): | 14.13 | Half-life (T1/2): | 0.867 |
| hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.05 |
| Drug-inuced Liver Injury (DILI): | 0.928 | AMES Toxicity: | 0.099 |
| Rat Oral Acute Toxicity: | 0.073 | Maximum Recommended Daily Dose: | 0.027 |
| Skin Sensitization: | 0.89 | Carcinogencity: | 0.117 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.408 |
| Respiratory Toxicity: | 0.13 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002587 | ![]() |
0.587 | D04XEG | ![]() |
0.400 | ||
| ENC001438 | ![]() |
0.541 | D07MGA | ![]() |
0.384 | ||
| ENC000107 | ![]() |
0.507 | D04AIT | ![]() |
0.365 | ||
| ENC001548 | ![]() |
0.468 | D06TJJ | ![]() |
0.354 | ||
| ENC001533 | ![]() |
0.462 | D06KYN | ![]() |
0.352 | ||
| ENC001550 | ![]() |
0.462 | D0J7RK | ![]() |
0.348 | ||
| ENC004231 | ![]() |
0.447 | D0K8KX | ![]() |
0.341 | ||
| ENC005357 | ![]() |
0.430 | D0U3YB | ![]() |
0.341 | ||
| ENC002571 | ![]() |
0.429 | D0AZ8C | ![]() |
0.322 | ||
| ENC002499 | ![]() |
0.423 | D0S2BV | ![]() |
0.316 | ||